KRAS G12C colorectal cancer: sotorasib + panitumumab breakthrough
CodeBreak300 phase 3: Lumakras and Vectibix combination increased progression-free survival by 3 months. Treatment of KRAS G12C metastases approved. How dual blockade breaks 40-year resistance.
